Stock Information

• Denali Therapeutics shares are trading higher after the company announced it secured $200 million in gross proceeds under the Royalty Agreement.
  Tue, Mar 31, 2026 9:09 AM
• Denali Therapeutics Secures $200M Royalty Funding Following U.S. FDA Accelerated Approval Of Tividenofusp Alfa
  Tue, Mar 31, 2026 8:36 AM
• Denali Therapeutics Inc. (DNLI) Discusses FDA Approval and Commercial Launch Plans for AVLAYAH for Hunter Syndrome - Slideshow
  Fri, Mar 27, 2026 7:15 PM
• Morgan Stanley Maintains Overweight on Denali Therapeutics, Raises Price Target to $42
  Thu, Mar 26, 2026 1:46 PM
• Goldman Sachs Maintains Buy on Denali Therapeutics, Raises Price Target to $40
  Thu, Mar 26, 2026 11:37 AM
• Stifel Maintains Buy on Denali Therapeutics, Raises Price Target to $41
  Thu, Mar 26, 2026 10:36 AM
• Arm Holdings To Rally Over 27%? Here Are 10 Top Analyst Forecasts For Thursday
  Thu, Mar 26, 2026 9:08 AM
• FDA Clears Denali Therapeutics Drug As First Brain-Penetrating Biologic For Rare Disease
  Thu, Mar 26, 2026 8:30 AM
• Baird Maintains Outperform on Denali Therapeutics, Raises Price Target to $32
  Thu, Mar 26, 2026 7:51 AM
• HC Wainwright & Co. Maintains Buy on Denali Therapeutics, Raises Price Target to $42
  Thu, Mar 26, 2026 7:37 AM

Financial data not available